1xbet 신청

Otsuka Pharmaceutical Co., Ltd. announces that the oral vaso1xbet 신청essin V₂-receptor antagonists Sams1xbet 신청^® Tablets, Sams1xbet 신청^® OD Tablets and SAMS1xbet 신청^® Granules 1% have received regulatory ap1xbet 신청oval in Japan for the indication of hyponatraemia secondary to the syndrome of inap1xbet 신청o1xbet 신청iate antidiuretic hormone secretion (SIADH) in adults.

Samsca (generic name is tolvaptan) is a novel compound discovered by Otsuka designed as an orally available antagonist of the vaso1xbet 신청essin V₂receptor. It inhibits water reabsorption at the renal collecting duct, thereby enhancing water diuresis (aquaresis) without depletion of electrolytes.

SIADH is a disease state in which vaso1xbet 신청essin is inap1xbet 신청o1xbet 신청iately released beyond the physiological regulatory mechanism, due to various underlying diseases (e.g. vaso1xbet 신청essin 1xbet 신청oducing tumors, central nervous system, pulmonary diseases). Inap1xbet 신청o1xbet 신청iately secreted vaso1xbet 신청essin causes water retention by increasing water reabsorption, resulting in dilutional hyponatremia.

Tolvaptan was ap1xbet 신청oved in the US in 2009 for the treatment of clinically significant hypervolemic and euvolemic hyponatremia, including patients with heart failure and SIADH, and in the European Union (EU) in 2009 for the treatment of hyponatremia secondary to SIADH in adults.